Transforming Osteoarthritis Care: LEVI-04 as a Next-Generation Non- Opioid Analgesic
- Mode of action of LEVI-04 as a first-in-class disease-modifying agent for osteoarthritis (OA)
- Safety & efficacy data from a 500-patient Phase 2 clinical study; findings, conclusions and learnings to take forward
- Insights into chronic pain in OA and the role of bone marrow lesions